Study evaluates DNAm PhenoAge as epigenetic biomarker for perioperative risk in adult spinal deformity surgeries
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
Researchers reported that the epigenetic biomarker DNAm PhenoAge consistently improved perioperative risk stratification models for adult spinal deformity surgeries compared to chronological age, indicating potential clinical utility for predicting surgical complications.
What happened
A multicenter adult spinal deformity (ASD) registry study analyzed clinical and laboratory data from 200 patients to compare DNAm PhenoAge and chronological age as predictors of postoperative adverse events.
The mean DNAm PhenoAge of the cohort was 53.7 ± 18.1 years, which was statistically lower than the mean chronological age of 61.1 ± 15.4 years (p < 0.001; 95% CI, 6.3–8.5).
Models incorporating DNAm PhenoAge demonstrated numerically higher discrimination for all examined surgical outcomes, showing an Area Under the Curve (AUC) range of 0.701–0.823 compared to 0.671–0.767 for chronological age models, though direct DeLong comparisons did not reach statistical significance (all p > 0.05).
Model fit metrics consistently favored the DNAm PhenoAge models (ΔAIC range of 4.41–7.08), with Net Reclassification Improvement (NRI) ranging from 0.198 to 0.500, indicating superior classification performance.
Why it matters
Chronological age is often an imprecise measure of physiological resilience, particularly in geriatric surgical populations where frailty and comorbid burden vary widely.
This study offers level 3 evidence that epigenetic aging clocks can improve predictive modeling for complex, high-risk orthopedic surgeries.
Consistently superior model fit and reclassification performance (indicated by NRI) suggest that biological age assessments could refine patient selection and preoperative optimization protocols.
Market impact
These findings support the clinical translation of epigenetic clocks, shifting their market perception from consumer wellness novelty to actionable clinical diagnostics.
The potential clinical integration of biological aging metrics could catalyze partnerships between diagnostic developers and major hospital networks looking to reduce postoperative readmissions and associated care costs.
What comes next
Larger prospective clinical trials to validate the predictive superiority of DNAm PhenoAge over standard frailty indexes and chronological age.
The development and regulatory clearance of rapid, cost-effective epigenetic diagnostic assays designed for preoperative hospital settings.
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH